Cargando…

Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers

Vaccination is the most important way to control infectious bronchitis (IB) in chickens. Since the end of 2015, the Delmarva (DMV)/1639 strain of infectious bronchitis virus (IBV) has caused significant damage to the layer flocks in Eastern Canada. The efficacy of a combination of existing IB vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Mohamed S. H., Buharideen, Sabrina M., Ali, Ahmed, Najimudeen, Shahnas M., Goldsmith, Dayna, Coffin, Carla S., Cork, Susan C., van der Meer, Frank, Abdul-Careem, Mohamed Faizal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416550/
https://www.ncbi.nlm.nih.gov/pubmed/36016082
http://dx.doi.org/10.3390/vaccines10081194
_version_ 1784776506655899648
author Hassan, Mohamed S. H.
Buharideen, Sabrina M.
Ali, Ahmed
Najimudeen, Shahnas M.
Goldsmith, Dayna
Coffin, Carla S.
Cork, Susan C.
van der Meer, Frank
Abdul-Careem, Mohamed Faizal
author_facet Hassan, Mohamed S. H.
Buharideen, Sabrina M.
Ali, Ahmed
Najimudeen, Shahnas M.
Goldsmith, Dayna
Coffin, Carla S.
Cork, Susan C.
van der Meer, Frank
Abdul-Careem, Mohamed Faizal
author_sort Hassan, Mohamed S. H.
collection PubMed
description Vaccination is the most important way to control infectious bronchitis (IB) in chickens. Since the end of 2015, the Delmarva (DMV)/1639 strain of infectious bronchitis virus (IBV) has caused significant damage to the layer flocks in Eastern Canada. The efficacy of a combination of existing IB vaccines licensed in Canada was assessed against experimental challenge with this IBV strain. The layer pullets were vaccinated during the rearing phase with live attenuated IB vaccines of Massachusetts (Mass) + Connecticut (Conn) types followed by an inactivated IB vaccine of Mass + Arkansas (Ark) types and then challenged with the Canadian IBV DMV/1639 strain at 30 weeks of age. Protection was evaluated based on the egg laying performance, immune responses, viral shedding, and viral genome loads and lesions in IBV target organs. The vaccinated challenged hens were protected from the drop in egg production observed in the non-vaccinated challenged hens. Early (5 dpi) anamnestic serum antibody response was measured in the vaccinated challenged hens as well as a significant level of antibodies was detected in the oviduct washes (14 dpi). In contrast, hens in the non-vaccinated challenged group showed delayed (12 dpi) and significantly lower serum antibody response. Viral RNA loads were reduced in the respiratory, alimentary, and reproductive tissues of the vaccinated challenged hens compared to the non-vaccinated challenged hens. Compared to the control groups, the vaccinated challenged hens had less marked microscopic lesions in the trachea, kidney, magnum, and uterus. Our experimental model demonstrated inconclusive results for cell-mediated immune responses and viral shedding. Overall, the vaccination program used in this study minimized viral replication and histopathological changes in most IBV target organs and protected challenged hens against drop in egg production.
format Online
Article
Text
id pubmed-9416550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94165502022-08-27 Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers Hassan, Mohamed S. H. Buharideen, Sabrina M. Ali, Ahmed Najimudeen, Shahnas M. Goldsmith, Dayna Coffin, Carla S. Cork, Susan C. van der Meer, Frank Abdul-Careem, Mohamed Faizal Vaccines (Basel) Article Vaccination is the most important way to control infectious bronchitis (IB) in chickens. Since the end of 2015, the Delmarva (DMV)/1639 strain of infectious bronchitis virus (IBV) has caused significant damage to the layer flocks in Eastern Canada. The efficacy of a combination of existing IB vaccines licensed in Canada was assessed against experimental challenge with this IBV strain. The layer pullets were vaccinated during the rearing phase with live attenuated IB vaccines of Massachusetts (Mass) + Connecticut (Conn) types followed by an inactivated IB vaccine of Mass + Arkansas (Ark) types and then challenged with the Canadian IBV DMV/1639 strain at 30 weeks of age. Protection was evaluated based on the egg laying performance, immune responses, viral shedding, and viral genome loads and lesions in IBV target organs. The vaccinated challenged hens were protected from the drop in egg production observed in the non-vaccinated challenged hens. Early (5 dpi) anamnestic serum antibody response was measured in the vaccinated challenged hens as well as a significant level of antibodies was detected in the oviduct washes (14 dpi). In contrast, hens in the non-vaccinated challenged group showed delayed (12 dpi) and significantly lower serum antibody response. Viral RNA loads were reduced in the respiratory, alimentary, and reproductive tissues of the vaccinated challenged hens compared to the non-vaccinated challenged hens. Compared to the control groups, the vaccinated challenged hens had less marked microscopic lesions in the trachea, kidney, magnum, and uterus. Our experimental model demonstrated inconclusive results for cell-mediated immune responses and viral shedding. Overall, the vaccination program used in this study minimized viral replication and histopathological changes in most IBV target organs and protected challenged hens against drop in egg production. MDPI 2022-07-27 /pmc/articles/PMC9416550/ /pubmed/36016082 http://dx.doi.org/10.3390/vaccines10081194 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hassan, Mohamed S. H.
Buharideen, Sabrina M.
Ali, Ahmed
Najimudeen, Shahnas M.
Goldsmith, Dayna
Coffin, Carla S.
Cork, Susan C.
van der Meer, Frank
Abdul-Careem, Mohamed Faizal
Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers
title Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers
title_full Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers
title_fullStr Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers
title_full_unstemmed Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers
title_short Efficacy of Commercial Infectious Bronchitis Vaccines against Canadian Delmarva (DMV/1639) Infectious Bronchitis Virus Infection in Layers
title_sort efficacy of commercial infectious bronchitis vaccines against canadian delmarva (dmv/1639) infectious bronchitis virus infection in layers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416550/
https://www.ncbi.nlm.nih.gov/pubmed/36016082
http://dx.doi.org/10.3390/vaccines10081194
work_keys_str_mv AT hassanmohamedsh efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT buharideensabrinam efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT aliahmed efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT najimudeenshahnasm efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT goldsmithdayna efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT coffincarlas efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT corksusanc efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT vandermeerfrank efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers
AT abdulcareemmohamedfaizal efficacyofcommercialinfectiousbronchitisvaccinesagainstcanadiandelmarvadmv1639infectiousbronchitisvirusinfectioninlayers